Antihemophilic factor, PEGylated, Recombinant Human coagulation factor VIII/F8
The product is a recombinant full-length human coagulation factor VIII (2,332 amino acids with a molecular weight (MW) of 280 kDa) covalently conjugated with at least one molecule of polyethylene glycol (MW 20 kDa). It is purified from the culture medium using several chromatography columns. The purification process includes immunoaffinity chromatography, in which a monoclonal antibody directed against factor VIII is promoted to selectively isolate the factor VIII from the medium. The production process includes a viral inactivation solvent-detergent treatment step. The product molecule is then covalently conjugated with the polyethylene glycol, which primarily targets lysine residues.
Full Length F8
<0.001 EU per 1 μg of the peptide by the LAL method
Antihemophilic Factor (Recombinant), PEGylated
For the treatment of hemophilia A (congenital factor VIII deficiency).This medication is a human antihemophilic factor indicated in adolescent and adult patients (12 years and older) with hemophilia A (congenital factor VIII deficiency). It is also used for on-demand treatment and control of bleeding and routine prophylaxis of bleeding episodes. It is not indicated for the treatment of von Willebrand disease.
Examples of Clinical Use:
Hemophilia A (congenital factor VIII deficiency)
Hemophilia A patients have a deficiency of factor VIII, resulting in a prolonged, patient plasma clotting time as indicated by the activated partial thromboplastin time (aPTT). Treatment with recombinant factor VIII normalizes the aPTT. Hemophilia A is a sex-linked hereditary disorder of blood coagulation caused by decreased levels of Factor VIII activity, resulting in profuse bleeding into the joints, muscles or internal organs, spontaneously/as a result of trauma. The administration of this drug increases plasma concentrations of factor VIII and serves to temporarily correct the coagulation disorder in hemophilia A patients.One study found that BAX 855, a pegylated full-length recombinant factor VIII with extended half-life, was very effective in the prevention and treatment of bleeding episodes.
Mechanism of action:
This medication temporarily replaces the missing coagulation factor VIII, required for effective hemostasis in patients with congenital hemophilia A.
Target 1. von Willebrand factor; Target 2. Coagulation factor IX; Target 3. Coagulation factor X; Enzyme 1. von Willebrand factor; Enzyme 2. Phosphatidylcholine transfer protein
For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products
without prior written approval from Creative BioMart.
For more information on how our products could help advance your project, please contact us.